Physician profile

Catelyn Vanauken Inman

Psychiatric/Mental Health (Nurse Practitioner) · Statesville, NC

NPI 1356977623

$298.60

in general payments reported to CMS, 2019-2025

6 companies · none reported in 2025

See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$70.13
Education$46.91

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Neurocrine Biosciences, INC. $125.00 2021
Abbvie INC. $62.61 2021-2024
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $46.91 2023
Teva Pharmaceuticals USA, INC. $30.13 2021
Supernus Pharmaceuticals, INC. $21.39 2023 Qelbree
Takeda Pharmaceuticals U.S.A., INC. $12.56 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Catelyn Vanauken Inman

$298.60

in general payments reported 2019-2025

Years
2021-2024
Top company
Neurocrine Biosciences, INC.

https://glasscript.com/doctor/11022230/catelyn-vanauken-inman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.